SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tom DuBois who wrote (2431)10/21/1997 8:48:00 PM
From: JOHN W.   of 6136
 
<does anyone see anything of substance on the near horizon that will propel AGPH toward John W's "70 by Nov"?>

To amplify: YES!!! From RS&C (10/20/97):

1) Continuation of Phase III studies Thymitaq in head & neck and liver cancer.

2) Filing of IND for AG3340. (huh?)

3) Phase I data from AG2034 (Gart Inhibitor) expected 2H:97.

4) Continuation of Phase IV program for Viracept, including results from ongoing double protease inhibitor trials expected late 1997 and early 1998.

5) Additional corporate collaborations.

6) Additional geographic approvals for viracept.

IMHO, European approval anticipation will drive at least to 75 (then quickly sell off after approval).

A third consecutive blow-out quarter, (3 quarters is what Metcalf has pointed out to as significant.)

Also, announcement regarding the rhinovirus selection (within a couple of weeks) and entrance into clinical trials.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News